Global Coalition for Adaptive Research - Driving Progress for Patients – Faster. Together.Global Coalition for Adaptive ResearchGlobal Coalition for Adaptive ResearchGlobal Coalition for Adaptive Research

Driving Progress for Patients – Faster. Together.

DONATE
  • Meet GCAR
    • About Us
    • Executive Team
    • Board of Directors
    • Trials Leadership
    • Global Sites
    • Contact Us
  • Discover Our Research
    • Master Protocols & Adaptive Platform Trials
    • GBM AGILE
      • GBM AGILE | Overview
      • Leadership Council
      • Trial Sites
      • Partners
      • Patient FAQs
    • DOD M-PACT PTSD
      • DOD M-PACT PTSD | Overview
      • Trial Sites
    • REMAP-CAP / COVID
      • REMAP-CAP / COVID | Overview
      • US Steering Committee
      • Trial Sites
      • Partners
      • Patient FAQs
    • IN DEVELOPMENT
      • OVARIAN CANCERX
        • OVARIAN CANCERX | Overview
        • Leadership
        • Partners
      • ARBOR BTC | Overview
      • Neurofibromatosis Platform Trial | Overview
      • IMPACT PDAC | Overview
  • Get News + Publications
    • Scientific Presentations + Publications
    • Educational Resources
      • White Papers
      • Video Resources
      • Infographics
    • News + Announcements
  • Make Progress
    • Support a Trial
    • Partner With Us
    • Contact Us
  • DONATE

Posts classified under: REMAP-CAP / COVID

News + Announcements
  • GBM AGILE
  • REMAP-CAP / COVID
  • M-PACT (PTSD)
  • Ovarian CanceRx
  • General
  • View All

Global Study on COVID-19 Treatments: Simvastatin and Vitamin C Results

October 25, 2023  |  BUSINESSWIRE

GCAR Discontinues Eritoran Evaluation in REMAP-COVID Trial

May 19, 2022  |  BUSINESSWIRE

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

August 4, 2021  |  NEJM

GCAR Announces Discontinued Evaluation of Apremilast in REMAP-COVID

July 12, 2021  |  BUSINESSWIRE

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

February 25, 2021  |  NEJM

Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system—lessons learned and recommendations

January 28, 2021  |  BIOMED CENTRAL

Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients

January 22, 2021  |  NATIONAL INSTITUTES OF HEALTH

Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial

October 26, 2020  |  BUSINESSWIRE

Corticosteroids Improve Survival in Critically Ill COVID-19 Patients

September 2, 2020  |  EUREKALERT

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

September 2, 2020  |  JAMA

Steroids Can Be Lifesaving for Covid-19 Patients, Scientists Report

September 2, 2020  |  NEW YORK TIMES

REMAP-CAP to Partner With Eisai on Innovative Trial to Combat COVID

June 30, 2020  |  BUSINESSWIRE

International trial uses AI to rapidly identify optimal Covid-19 treatments

April 9, 2020  |  STAT

    From GCAR Twitter

 

Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) non-profit corporation pioneering collaborative, innovative clinical trials to speed the discovery and development of cures.
DRIVING PROGRESS FOR PATIENTS  — FASTER. TOGETHER.

 

FOR PARTICIPATING TRIAL LOCATIONS

GBM AGILE
Resource Portal

 

QUICK LINKS

  • Meet GCAR
  • Discover Our Research
  • GBM AGILE
  • DOD M-PACT PTSD
  • REMAP-CAP / COVID
  • Get News + Publications
  • Make Progress
  • Donate

RECENT POSTS

NEWS + ANNOUNCEMENTS

GCAR Welcomes Financial Visionary Andrew Lo to Board of Directors

Investigational Drug Tinostamustine to be Included in GBM AGILE Clinical Trial for Glioblastoma

GENERAL INQUIRIES

PARTNER INQUIRIES

 

©2026 GLOBAL COALITION FOR ADAPTIVE RESEARCH. ALL RIGHTS RESERVED.  •  PRIVACY